StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Sumeet Bagadia, Choice Broking

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

bySumeet Bagadia, Choice BrokingHorizon: NA (inferred 1–3 months)7 Nov 2026via LiveMint Markets

Entry₹1,861Inferred
Target₹2,050
Total upside +10.16%
Stop loss₹1,765-5.16% risk
CMP₹1,9152h ago
Active+2.90%+7.05%upside left 3 mo left
Follow Sumeet Bagadia for new calls(31% target hit, 49 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 84 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Nov, 6:52 pm IST
8 supporting4 neutral1 opposing
Supports the BUY call (8)

Muhurat Trading 2026: Finolex Cables Jumps 17% As Samvat 2083 Begins. These Stocks Are Also Rallying

NewsNdtv-Profit·8 Nov · today

(opens in new tab)

MACD above its signal line — bullish momentum

Technicals · macd·8 Nov · today

Past month's volume 1.3× the prior month's average

Technicals · volume·6 Nov · 2d ago

19 advisors have active long-term BUY calls on this stock, with 8 issued in the last 14 days

Advisor consensus · adjacent horizon·6 Nov · 2d ago

Sun Pharma shares extend 4-day rally after USFDA approval for ILUMYA in arthritis patients

NewsCnbc-Tv18·30 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (4)

Unaudited Financial Results for the quarter and half year ended 30 September 2026

NSE · Outcome of Board Meeting·30 Oct · 1w ago

(opens in new tab)

Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal

NewsEt-Markets·21 Oct · 3w ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3w ago

(opens in new tab)

CRISIL and ICRA have assigned ratings to the company's proposed non-convertible debenture programme and reaffirmed ratings on existing bank facilities and commercial paper.

BSE · Company Update·13 Oct · 4w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 77 — overbought territory

Technicals · rsi·8 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Sumeet Bagadia, Choice Broking

Every call and its outcome